TARRYTOWN, N.Y., May 10, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter ended March 31. Net loss for the quarter was $11.3 million or $0.22 diluted per share, compared to net loss of $13.1 million or $0.39 diluted per share in the 2012 period, due primarily to a $1.8 million decrease in total expenses. Progenics ended the quarter with cash, cash equivalents and securities of $58.4 million, reflecting use of $3.6 million for operations in the quarter. First quarter revenue totaled $2.2 million for the current and prior-year periods. Royalty income for 2013 first quarter was $1.2 million compared to $1.8 million in the 2012 period, based on Relistor ® net sales (in millions) reported to Progenics by Salix of:
|Three Months Ended|
|March 31,||December 31,|
|U.S.||$ 6.7||$ 11.3||$ 4.1|
|Global||$ 7.7||$ 12.3||$ 5.2|
First Quarter Events
- Progenics acquired Molecular Insight Pharmaceuticals, expanding its oncology pipeline with diagnostic and small molecule therapeutic candidates targeting prostate specific membrane antigen (PSMA) and prostate cancer.
- Relistor global net sales increased 47% over the previous quarter, and decreased 37% from the first quarter of 2012.
- Positive clinical data were reported from a study of two novel radiolabeled small molecule imaging agents targeting PSMA.
- The company reduced headcount, primarily at Molecular Insight, resulting in an approximate $1.5 million restructuring charge.
- Angelo W. Lovallo, Jr., was appointed Vice President, Finance of the company.
|PROGENICS PHARMACEUTICALS, INC.|
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except net loss per share)|
|For the Three Months Ended March 31,|
|Royalty income||$ 1,157||$ 1,834|
|Research and development||8,721||10,909|
|License fees – research and development||70||40|
|General and administrative||4,314||3,721|
|Depreciation and amortization||277||472|
|Total other income||14||15|
|Net loss||$ (11,258)||$ (13,086)|
|Net loss per share; basic and diluted||$ (0.22)||$ (0.39)|
|Weighted average shares outstanding; basic and diluted||50,116||33,761|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|March 31, 2013||December 31, 2012|
|Cash and cash equivalents||$ 55,284||$ 58,838|
|Auction rate securities||3,148||3,240|
|Fixed assets, net||3,384||3,399|
|Intangible assets and goodwill||40,002||--|
|Total assets||$ 105,333||$ 76,308|
|Current liabilities||$ 8,378||$ 8,662|
|Acquisition-related contingent consideration liability||15,900||--|
|Deferred tax and other liabilities||13,765||1,078|
|Total liabilities and stockholders' equity||$ 105,333||$ 76,308|
Important Safety Information for subcutaneous RelistorRelistor is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of Relistor beyond four months has not been studied. Relistor is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with Relistor and consult their physician. Use of Relistor has not been studied in patients with peritoneal catheters. Safety and efficacy of Relistor have not been established in pediatric patients. Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the GI tract (i.e., cancer, peptic ulcer, Ogilvie's syndrome). Perforations have involved varying regions of the GI tract (e.g., stomach, duodenum, colon). Use Relistor with caution in patients with known or suspected lesions of the GI tract. Advise patients to discontinue therapy with Relistor and promptly notify their physician if they develop severe, persistent, and/or worsening abdominal symptoms. The most common adverse reactions reported with Relistor compared with placebo in clinical trials were abdominal pain (28.5% vs. 9.8%), flatulence (13.3% vs. 5.7%), nausea (11.5% vs. 4.9%), dizziness (7.3% vs. 2.4%), diarrhea (5.5% vs. 2.4%), and hyperhidrosis (6.7% vs. 6.5%). Relistor full Prescribing Information for the U.S. is available at www.relistor.com. About Progenics Progenics Pharmaceuticals, Inc. is discovering and developing innovative medicines for oncology, with a pipeline that includes product candidates in preclinical through late-stage development. Progenics' first commercial product, Relistor ® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. For additional information, please visit www.progenics.com. This press release may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other development activities; the unpredictability of the duration and results of regulatory review of New Drug Applications and Investigational NDAs; market acceptance for approved products; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting matters, litigation and other risks. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the U.S. Securities and Exchange Commission. Progenics is providing the information in this press release as of its date and does not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise. Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this release. (PGNX-F)